Based on the Dermapharm Holding SE stock forecast from 0 analysts, the average analyst target price for Dermapharm Holding SE is not available over the next 12 months. Dermapharm Holding SE’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Dermapharm Holding SE is Neutral, which is based on 6 positive signals and 6 negative signals. At the last closing, Dermapharm Holding SE’s stock price was EUR 31.05. Dermapharm Holding SE’s stock price has changed by -2.36% over the past week, -6.81% over the past month and -32.50% over the last year.
No recent analyst target price found for Dermapharm Holding SE
No recent average analyst rating found for Dermapharm Holding SE
Company Overview Dermapharm Holding SE
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription healthcare products, herbal extracts, and other pharmaceutical products. It offers healthcare products in the areas of vitamins, minerals, food supplements, dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology. The company also provides medical devices under the bite away and Herpotherm names. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. The company was founded in 1991 and is based in Grünwald, Germany. Dermapharm Holding SE operates as a subsidiary of Themis Beteiligungs-AG. Address: Lil-Dagover-Ring 7, Grünwald, Germany, 82031 Read Less
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal...Read More
Frequently Asked Questions About Dermapharm Holding SE (DMP:XETRA) Stock
Stock Target Advisor's fundamental analysis for Dermapharm Holding SE's stock is Neutral.
DMP:XETRA stock's dividend yield is 2.79%.
Our analysis grades DMP:XETRA stock's dividend yield at A+. This means that DMP:XETRA stock's dividend yield is above 100% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the XETRA exchange.
Based on this DMP:XETRA may be a good dividend stock for its sector.
Unfortunately we do not have enough data on DMP:XETRA's stock to indicate what its average analyst target is.
DMP:XETRA stock's Price/Earning ratio is 26.77.
Our analysis grades DMP:XETRA stock's Price / Earning ratio at F. This means that DMP:XETRA stock's Price/Earning ratio is above 67% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the XETRA exchange.
Based on this DMP:XETRA may be a overvalued for its sector.
The last closing price of DMP:XETRA's stock was EUR 31.05.
The most recent market capitalization for DMP:XETRA is EUR 1.71B.
Unfortunately we do not have enough analyst data on DMP:XETRA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Dermapharm Holding SE's stock.
As per our most recent records Dermapharm Holding SE has 3,497 Employees.
Dermapharm Holding SE's registered address is Lil-Dagover-Ring 7, Grünwald, Germany, 82031.
You can get more information about it from Dermapharm Holding SE's website at https://www.dermapharm.de.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for DMP:XETRA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
